NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/09/2026 14:26
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,568.52 mln
Float108 mln
Earnings Date08/06/2026
Piotroski F-Score
1
/ 9
Very weak
1-Year Forecast
39.87
Transformational upside
Relative Strength
71
/ 100
Outperforming
Debt / Equity
0.15
Very low leverage
ROE
-103
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Definium Therapeutics, based in New York, is a clinical-stage company focused on developing new treatments for mental health and brain-related conditions. Its most advanced drug, DT120, is currently in Phase 3 trials for generalized anxiety disorder and major depression, while a second compound, DT402, is in earlier trials targeting autism spectrum disorder. The company was previously called Mind Medicine (MindMed) before adopting its current name in January 2026.
